MedTrace Logo

Imaging NSCLC Treatment Response to Immunotherapy

NCT02753569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-02-01

No results posted yet for this study

Summary

This feasibility study will aim to assess the potential for functional imaging biomarkers (18FDG PET-CT and DW-MRI) to differentiate immunotherapy induced inflammation, indicative of response from non-response in patients with stage IV non-small cell lung cancer (NSCLC).

Conditions

Interventions

OTHER

Imaging - DW-MRI

RADIATION

FDG PET-CT

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Royal Marsden NHS Foundation Trust

    collaborator OTHER

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-05-14
Completion
2020-05-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02753569 on ClinicalTrials.gov